Mariner’s CAMP4 Therapeutics CAMP Stock Holding History

Mariner’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,371	Closed	-$94.2K	–	3597
2025 Q4	$94.2K	Sell	15,371 -1,927	-11%	-$8.2K	﹤0.01%	3339
2025 Q3	$51.9K	Buy	+17,298	New	+$32K	﹤0.01%	3444

Other funds holding CAMP

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mariner's CAMP Position: Q1 2026 in Review

Mariner sold out of CAMP4 Therapeutics (CAMP) in Q1 2026, closing a stake of 15,371 shares — an estimated $94.2K sold.

Mariner first reported a position in CAMP in Q3 2025 and held it in 2 quarters. The position peaked at $94.2K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

Mariner reported no remaining CAMP4 Therapeutics position as of Q1 2026 after selling out during the quarter.
Mariner sold 15,371 CAMP4 Therapeutics shares in Q1 2026, an estimated $94.2K.
Mariner first reported a position in CAMP4 Therapeutics in Q3 2025 and held it in 2 quarters.
Mariner's CAMP4 Therapeutics position peaked at $94.2K in Q4 2025.
46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.